ライフサイエンスコーパス: African trypanosomiasis

1 rming resurgence in sleeping sickness (human African trypanosomiasis).

2 as a promising therapeutic target for human African trypanosomiasis.

3 es as potential novel drug targets for human African trypanosomiasis.

4 Thus, PTR1 may be a drug target for human African trypanosomiasis.

5 development of new treatments against human African trypanosomiasis.

6 treatment and prevention of human and animal African trypanosomiasis.

7 n a highly reproducible mouse model of human African trypanosomiasis.

8 tial target for new compounds to treat human African trypanosomiasis.

9 of four animals in the acute mouse model of African trypanosomiasis.

10 provide variant cross-specific immunity for African trypanosomiasis.

11 inflammatory and regulatory mediators during African trypanosomiasis.

12 undergoing phase III clinical trials against African trypanosomiasis.

13 for inhibitors of therapeutic value against African trypanosomiasis.

14 TAO an important chemotherapeutic target for African trypanosomiasis.

15 keepers to control tsetse flies and, hence, African trypanosomiasis.

16 ated animals in the STIB900 animal model for African trypanosomiasis.

17 ich was developed for the treatment of human African trypanosomiasis.

18 +)-ATPases (PMCAs) of T. brucei, an agent of African trypanosomiasis.

19 teins for developing new serodiagnostics for African trypanosomiasis.

20 antimicrobial peptides for the treatment of African trypanosomiasis.

21 trypanosomes overcome host resistance during African trypanosomiasis.

22 o showed some in vivo activity in a model of African trypanosomiasis.

23 n-specific Th-cell responses in experimental African trypanosomiasis.

24 ocus on the parasites that cause malaria and African trypanosomiasis.

25 esiense or T.b. gambiense, which cause human African trypanosomiasis.

26 a: Glossinidae), vectors of Human and Animal African trypanosomiasis.

27 rm the backbone of the pharmacopoeia against African trypanosomiasis.

28 unique compounds for the treatment of human African trypanosomiasis.

29 al therapeutic target for treatment of human African trypanosomiasis.

30 urative in the STIB900 mouse model for human African trypanosomiasis.

31 osoma brucei is the causative agent of human African trypanosomiasis.

32 for the development of drugs to treat human African trypanosomiasis.

33 y as part of a combination therapy for human African trypanosomiasis.

34 c protozoan responsible for human and animal African trypanosomiasis.

35 n Trypanosoma brucei, the causative agent of African trypanosomiasis.

36 mising lead for development of drugs against African trypanosomiasis.

37 potential target for the treatment of human African trypanosomiasis.

38 anosoma brucei, the causative agent of human African trypanosomiasis.

39 anosoma brucei, the causative agent of human African trypanosomiasis.

40 discussed, with a particular focus on human African trypanosomiasis.

41 validated target for the treatment of human African trypanosomiasis.

42 Trypanosoma brucei is the causing agent of African trypanosomiasis.

43 parenchyma is a major pathogenetic event in African trypanosomiasis.

44 Animal African trypanosomiasis (AAT), caused by Trypanosoma con

45 o assess the efficacy of treatment for human African trypanosomiasis, accurate tests that can discrim

46 anosoma brucei, the causative agent of human African trypanosomiasis, affects tens of thousands of su

47 Human African trypanosomiasis, also known as sleeping sickness

48 Human African trypanosomiasis, also known as sleeping sickness

49 proteomic signatures characteristic of human African trypanosomiasis among 206 protein clusters.

50 applied serum samples from 85 patients with African trypanosomiasis and 146 control patients who had

51 ly related to the taxa responsible for human African trypanosomiasis and Chagas disease.

52 Trypanosoma brucei causes African trypanosomiasis and contains three full-length o

53 dentifies TbCLK1 as a therapeutic target for African trypanosomiasis and establishes a new chemoprote

54 Trypanosoma brucei causes fatal human African trypanosomiasis and evades the host immune respo

55 Trypanosoma brucei causes human African trypanosomiasis and regularly switches its major

56 Trypanosoma brucei causes human African trypanosomiasis and regularly switches its major

57 Trypanosoma brucei causes human African trypanosomiasis and regularly switches its major

58 ffolds within the GlaxoSmithKline HAT (Human African Trypanosomiasis) and Chagas chemical boxes, two

59 osoma brucei, the protozoan parasite causing African trypanosomiasis, and the tsetse (Glossina) vecto

60 All four main drugs used for human African trypanosomiasis are toxic, and melarsoprol, the

61 le is Trypanosoma brucei, which causes human African trypanosomiasis, as well as the livestock diseas

62 important option for reducing the impact of African trypanosomiasis but, although many effective met

63 lidated as new therapeutic targets for human African trypanosomiasis by both genetic and pharmacologi

64 p novel anti-inflammatory therapies in Human African trypanosomiasis by modulating the NK1 receptor a

65 for neglected parasitic diseases, including African trypanosomiasis caused by the protozoan, Trypano

66 re common, particularly in the case of Human African Trypanosomiasis caused by Trypanosoma brucei gam

67 a and comes in two types: East African human African trypanosomiasis caused by Trypanosoma brucei rho

68 Novel methods for treatment of African trypanosomiasis, caused by infection with Trypan

69 Human African trypanosomiasis, caused by the eukaryotic parasi

70 African sleeping sickness or human African trypanosomiasis, caused by Trypanosoma brucei sp

71 , and Leishmania spp., which in humans cause African trypanosomiasis, Chagas disease, and leishmanias

72 e developing world, including malaria, human African trypanosomiasis, Chagas disease, leishmaniasis,

73 um falciparum, the causative agents of human African trypanosomiasis, Chagas disease, leishmaniasis,

74 For selected causes (African trypanosomiasis, congenital syphilis, whooping c

75 Trypanosoma brucei, the causative agent of African trypanosomiasis, contains a soluble, vacuolar py

76 the number of reported cases, patients with African trypanosomiasis continue to present major challe

77 Treatment of human African trypanosomiasis currently relies on a limited nu

78 iont may also contribute to generating novel African trypanosomiasis disease control strategies.

79 Trypanosoma brucei, the etiological agent of African trypanosomiasis, disease progression can be rapi

80 The progression of human African trypanosomiasis from the early hemolymphatic sta

81 e in the pipeline for treatment of CNS human African trypanosomiasis, giving rise to cautious optimis

82 ificant human suffering in the form of human African trypanosomiasis (HAT) and Chagas disease.

83 Epidemics of both forms of human African trypanosomiasis (HAT) are confined to spatially

84 ing diagnostic and treatment tools for human African trypanosomiasis (HAT) are limited.

85 Human African trypanosomiasis (HAT) caused by Trypanosoma bruc

86 Human African trypanosomiasis (HAT) is a neglected tropical di

87 Human African trypanosomiasis (HAT) is a parasitic disease aff

88 Human African trypanosomiasis (HAT) or sleeping sickness is ca

89 i (T. brucei), the causative agent for human African trypanosomiasis (HAT) or sleeping sickness.

90 Human African trypanosomiasis (HAT), a major health concern in

91 genetically validated drug target for human African trypanosomiasis (HAT), also called African sleep

92 soma brucei, the causative parasite of human African trypanosomiasis (HAT), also known as African sle

93 Human African trypanosomiasis (HAT), also known as sleeping si

94 rtality worldwide; four in particular (human African trypanosomiasis (HAT), Chagas disease, cutaneous

95 The resurgence of human African trypanosomiasis (HAT), coupled with an increased

96 brucei, protozoan parasites that cause human African trypanosomiasis (HAT), depend on ornithine uptak

97 lt of their protective effects against human African trypanosomiasis (HAT), or African sleeping sickn

98 Human African trypanosomiasis (HAT), or sleeping sickness, is

99 rtant drug target for the treatment of human African trypanosomiasis (HAT), raising interest in under

100 ted immunity, the parasites that cause human African Trypanosomiasis (HAT), Trypanosoma brucei rhodes

101 agnostic serum proteomic signature for human African trypanosomiasis (HAT), using a combination of su

102 represents a promising drug target for human African trypanosomiasis (HAT), which is caused by the pa

103 ist parasite Trypanosoma brucei causes Human African trypanosomiasis (HAT), which threatens millions

104 Trypanosoma brucei causes human African trypanosomiasis (HAT).

105 he late (meningoencephalitic) stage of human African trypanosomiasis (HAT).

106 nosoma brucei causes the fatal illness human African trypanosomiasis (HAT).

107 central nervous system second stage of human African trypanosomiasis (HAT).

108 ccurred as a result of protection from human African trypanosomiasis (HAT).

109 herapeutic target for the treatment of human African trypanosomiasis (HAT).

110 ed for their potential toward treating human African trypanosomiasis (HAT).

111 hat emerged remain in use for treating human African trypanosomiasis (HAT).

112 Uganda has both forms of human African trypanosomiasis (HAT): the chronic gambiense dis

113 eroon, a historical focus of gambiense Human African Trypanosomiasis (HAT, sleeping sickness), a dise

114 Trypanosoma brucei sp. causes human African trypanosomiasis (HAT; African sleeping sickness)

115 causative agent of sleeping sickness (Human African Trypanosomiasis, HAT), contains a kinetoplast wi

116 for the control of sleeping sickness (human African trypanosomiasis, HAT).

117 rasitic protozoan and the causative agent of African trypanosomiasis, imports about a thousand protei

118 y was applied to a use case of resistance to African trypanosomiasis in the mouse.

119 rug will be developed for treatment of human African trypanosomiasis in the near future, increasing a

120 These results implicate both forms of human African trypanosomiasis in the selection and persistence

121 ne), which is used clinically to treat human African trypanosomiasis, inhibits the first step in poly

122 Relative resistance to African trypanosomiasis is based on the development of a

123 Human African trypanosomiasis is caused by a single-celled pro

124 Human African trypanosomiasis is caused by the eukaryotic micr

125 ated molecular target for treatment of human African trypanosomiasis is ornithine decarboxylase (ODC)

126 Host resistance to African trypanosomiasis is partially dependent on an ear

127 The treatment of both human and veterinary African trypanosomiasis is still, to a large extent, dep

128 current chemotherapy for second stage human African trypanosomiasis is unsatisfactory.

129 The urgent need for new drug development for African trypanosomiasis is widely recognized.

130 te, Trypanosoma brucei, a causative agent of African trypanosomiasis, is unknown.

131 The parasite Trypanasoma brucei causes African trypanosomiasis, known as sleeping sickness in h

132 anosoma brucei, the causative agent of human African trypanosomiasis, led to the identification of su

133 ation, maturation, and Ig class switching in African trypanosomiasis may be partially regulated by un

134 cancer, diabetes, cirrhosis, Chagas disease, African trypanosomiasis, melanoma, and others.

135 sign of adenosine analogues as drugs against African trypanosomiasis, N(6)-, 2-amino-N(6)-, and N(2)-

136 Human African trypanosomiasis or sleeping sickness is a deadly

137 tity was added to the pharmacopeia for human African trypanosomiasis (or sleeping sickness), orally d

138 Human African trypanosomiasis, or sleeping sickness, is caused

139 Human African trypanosomiasis, or sleeping sickness, is caused

140 both a veterinary wasting disease and human African trypanosomiasis, or sleeping sickness.

141 sponsible for the fatal human disease called African trypanosomiasis, or sleeping sickness.

142 t Trypanosoma brucei, the causative agent of African trypanosomiasis, possesses a bona fide member of

143 anosoma brucei, the causative agent of human African trypanosomiasis, possesses non-canonical mitocho

144 anosoma brucei, the causative agent of human African trypanosomiasis, possesses two fatty acid synthe

145 The treatment of Human African trypanosomiasis remains a major unmet health nee

146 mbination therapy for the treatment of human African trypanosomiasis, renewing interest in nitroheter

147 ne models of both early and late stage human African trypanosomiasis, representing a new lead for the

148 Human African trypanosomiasis (sleeping sickness) affects up t

149 anosoma brucei, the causative agent of Human African Trypanosomiasis (sleeping sickness), yet little

150 ood parasite Trypanosoma brucei causes human African trypanosomiasis ("sleeping sickness") across sub

151 nce to present front line drugs for treating African trypanosomiasis such as melarsoprol (Arsobal) an

152 is a more specific marker for cure of human African trypanosomiasis than parasite DNA.

153 e critically involved in the pathogenesis of African trypanosomiasis, the contributions to this disea

154 anosoma brucei, the causative agent of human African trypanosomiasis, the NDR kinase, PK50, is expres

155 f glycolysis in the causative agent of human African trypanosomiasis, Trypanosoma brucei, has already

156 The causative agent of human African trypanosomiasis, Trypanosoma brucei, lacks de no

157 Trypanosoma brucei, the causative agent for African trypanosomiasis undergoes various stages of cell

158 ucei, a protozoan parasite that causes human African trypanosomiasis, uses antigenic variation as a m

159 ples obtained from 61 patients in whom human African trypanosomiasis was cured, SL RNA detection had

160 smodium falciparum malaria, melioidosis, and African trypanosomiasis, were reported.

161 develop a novel test that can diagnose human African trypanosomiasis with high sensitivity and specif